Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BALZIVA-21 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy,Treatment of non-small cell lung cancer (first-line) in combination with carboplatin and paclitaxel,Treatment of glioblastoma as monotherapy in patients with progressive disease following prior therapy,Treatment of metastatic renal cell carcinoma in combination with interferon alfa
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
BALZIVA-21 is administered 150 mg orally twice daily.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Metabolized by proteolytic degradation into small peptides and amino acids via catabolic pathways; not metabolized by CYP450 enzymes.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
95% bound to albumin and alpha-1-acid glycoprotein
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Vd: 0.8 L/kg (reflects extensive tissue distribution)
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 75% (first-pass effect reduces from 100%)
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
Cr Cl 30-60 m L/min: 75 mg twice daily. Cr Cl 15-29 m L/min: 75 mg once daily. Cr Cl <15 m L/min or hemodialysis: 75 mg after each dialysis session.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh A: no adjustment. Child-Pugh B: 75 mg twice daily. Child-Pugh C: not recommended.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not established for patients under 18 years.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No specific adjustment; monitor renal function and consider age-related decline in Cr Cl.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Gastrointestinal perforation, wound dehiscence, and hemorrhage: BALZIVA-21 can cause serious and fatal gastrointestinal perforations, wound healing complications, and severe hemorrhage. Treatment should not be initiated for at least 28 days after major surgery and until the surgical wound is fully healed.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, reversible posterior leukoencephalopathy syndrome (RPLS), infusion-related reactions, and proteinuria including nephrotic syndrome.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Hypersensitivity to BALZIVA-21 or any excipients; untreated hypertension with systolic >150 mm Hg or diastolic >100 mm Hg; recent major surgery (within 28 days); history of arterial thromboembolic events (e.g., myocardial infarction, stroke) within 6 months; serious bleeding diathesis or coagulopathy; metastatic colorectal cancer involving the trachea, bronchi, or esophagus with cavitation or hemoptysis.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice, which may increase BALZIVA-21 levels. No other significant dietary restrictions. Maintain consistent vitamin K intake if also taking warfarin, but not applicable as BALZIVA-21 is a factor Xa inhibitor.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
First trimester: Known teratogen. Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) with exposure. Second and third trimesters: Fetal toxicity, including oligohydramnios and fetal renal impairment, is well-documented. Avoid use throughout pregnancy unless no alternative and benefit justifies risk.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Unknown whether Balziva-21 or its metabolites are excreted in human milk. M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Increased clearance and altered volume of distribution during pregnancy may necessitate dose adjustments. Contraindicated in pregnancy, but if unavoidable, therapeutic drug monitoring and dose titration based on serum levels may be required; however, no established dosing guidelines exist.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
BALZIVA-21 is a novel oral anticoagulant (factor Xa inhibitor) with a half-life of 21 hours, allowing once-daily dosing. No routine coagulation monitoring is required. Reversal agent (andexanet alfa) is available for life-threatening bleeding. Avoid in severe hepatic impairment (Child-Pugh C). Adjust dose in renal impairment (Cr Cl <30 m L/min: reduce dose by 50%).
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take exactly as prescribed at the same time each day.,Do not stop taking without consulting your doctor, as this increases stroke risk.,Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless directed by your doctor.,Inform all healthcare providers, including dentists, that you are taking this medication.,If a dose is missed, take it as soon as remembered if within 12 hours; otherwise skip and resume next day.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BALZIVA-21 vs ALTAVERA, answered by our medical review team.
BALZIVA-21 is a Oral Contraceptive that works by BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BALZIVA-21 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BALZIVA-21 is: BALZIVA-21 is administered 150 mg orally twice daily.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BALZIVA-21 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BALZIVA-21 is classified as Category C. First trimester: Known teratogen. Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) with exposure. Second and third trimesters: Fetal. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.